GE MEDICAL SYSTEMS

Biopsy samples from brain tumor bank at Columbia University were de-identified and analyzed in alignment with WMA Declaration of Helsinki. Tissue samples were divided, one part H&E stained, the other stored at −80°C. Spatial alignment between biopsy samples and imaging data was ensured using custom registration software and FSL. Three tissue-specific gene modules (Neu, Pro, Inf) were identified through RNAseq-IHC correlation analysis and GSVA. RNA extraction and PLATE-Seq were performed for transcriptome expression. IHC staining and quantification were done for SOX2, Ki67, CD68, and NeuN. MRI sequences included T1Gd, T2, FLAIR, ADC, and SWI. BioNet, a multitask semi-supervised learning model, was constructed to predict gene module expression using both labeled and unlabeled samples, incorporating domain knowledge and UQ.

GE predicted digital twins could monitor health metrics by 2017, with 800,000 twins already monitoring machines. In 2024, NSF announced $6 million in funding for digital twin projects in healthcare, aiming to reduce medical risks and streamline clinical trials.

GE HealthCare partners with University Medicine Essen to establish a Theranostics Centre of Excellence in Germany, aiming to enhance precision care and expand access to personalised cancer treatment. The centre will utilize advanced technologies, including molecular imaging and AI-enhanced systems, to support clinical practice and research, promoting personalised cancer care globally.

GE HealthCare collaborates with University Medicine Essen to establish a Theranostics Center of Excellence, aiming to advance personalized cancer care through precision diagnostics, advanced imaging, and AI solutions.

The global Genomics in Cancer Care market is projected to grow from $21.4B in 2023 to $62.1B by 2030, driven by personalized medicine, advancements in genetic testing, and targeted therapies. North America leads, while Asia-Pacific emerges as a key growth region.

GE HealthCare collaborates with Blackford to integrate AI into radiology workflows, aiming to alleviate radiologist burnout and enhance diagnostic precision and patient care outcomes.

DelveInsight's report on Congestive Heart Failure Market (2020-2034) covers epidemiology, market trends, key companies, and therapies. Market size was ~USD 6,900 million in 2023, expected to grow significantly. Key companies include Novartis, Bayer, and Eli Lilly. Therapies like ENTRESTO and JARDIANCE are highlighted. Market drivers include aging population and disease prevalence, while barriers include generic therapies and diagnostic challenges.

The nanomedicine market was valued at USD 223.6 billion in 2023 and is projected to reach USD 634.2 billion by 2032, with a CAGR of 12.2%. This growth is driven by increased demand for advanced drug delivery systems and rising chronic disease incidence. North America leads the market, while Asia-Pacific is expected to grow the fastest.

The nanomedicine market, valued at USD 223.6 billion in 2023, is projected to reach USD 634.2 billion by 2032, driven by advanced drug delivery systems and rising chronic diseases. Key players include Johnson & Johnson, Mallinckrodt Pharmaceuticals, and Teva Pharmaceutical Industries. Recent developments include Novartis's nanoparticle-based ovarian cancer treatment and Merck's partnership with Stanford for immunotherapy research.

Genomic DNA extraction and NGS library preparation were performed using specific kits and protocols, with quality checks conducted via Qubit™ and Bioanalyzer. The HRDetect pipeline was developed to replicate Davies et al.'s results, requiring BAM file annotation, variant calling, filtering, and HRDetect method calling. The HRDirect pipeline was created to be independent of normal data, using a meta-normal sample and various variant filtering strategies. Tumor samples were obtained from patients with informed consent, and organoids were established and characterized. Immunohistochemical and Western blot analyses were conducted on organoids to study protein expression. HRD scores were assessed using targeted sequencing panels and proprietary algorithms.